Mark T. Fleming, MD

Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.

Darolutamide, enzalutamide (Xtandi), and apalutamide (Erleada) have all demonstrated promising findings, signifying that therapies are moving forward in this space. It is exciting to see that patients now have a lot of options, Fleming says.

Mark T. Fleming, MD | Authors

Articles

Dr. Fleming Shares Encouraging Data With Antiandrogen Therapies in Prostate Cancer